Get the Stockscreener App
3.8125
6.57%
0.2351
After Hours:
3.81
-0.0025
-0.07%
Molecular Partners Ag Adr stock is traded at $3.8125, with a volume of 2,473.
It is up +6.57% in the last 24 hours and up +1.13% over the past month.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
See More
Previous Close:
$3.5775
Open:
$3.86
24h Volume:
2,473
Relative Volume:
0.25
Market Cap:
$153.95M
Revenue:
$7.80M
Net Income/Loss:
$-69.02M
P/E Ratio:
-1.7805
EPS:
-2.1413
Net Cash Flow:
$-66.61M
1W Performance:
-5.63%
1M Performance:
+1.13%
6M Performance:
-34.49%
1Y Performance:
-6.33%
1-Day Range:
$3.8125
$4.0793
1-Week Range:
$3.5775
$4.0793
52-Week Range:
$3.36
$12.70
Molecular Partners Ag Adr Stock (MOLN) Company Profile
Name
Molecular Partners Ag Adr
Sector
Industry
Phone
-
Address
-
Compare MOLN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MOLN
Molecular Partners Ag Adr
|
3.8125 | 148.97M | 7.80M | -69.02M | -66.61M | -2.1413 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Molecular Partners Ag Adr Stock (MOLN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-30-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-29-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-25-22 | Upgrade | Credit Suisse | Underperform → Neutral |
| Apr-27-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jul-13-21 | Initiated | Cowen | Outperform |
| Jul-12-21 | Resumed | SVB Leerink | Outperform |
View All
Molecular Partners Ag Adr Stock (MOLN) Latest News
Walmart, Deere, Applied Materials set to report earnings Thursday By Investing.com - Investing.com Nigeria
Walmart, Deere, Applied Materials set to report earnings Thursday - Investing.com
Ziff Davis Inc (NASDAQ:ZD) Shares Jumped 1.54% In A Week. Can It Continue Rising? - Marketing Sentinel
Can Contango ORE, Inc. (CTGO) Climb 163.28% to Reach the Level Wall Street Analysts Expect? - Yahoo Finance
Here's Why Molecular Partners AG Sponsored ADR (MOLN) Could be Great Choice for a Bottom Fisher - Yahoo Finance
Musk's DOGE Exit Rumors & Weak Q1 Deliveries: How to Play Tesla Now - Yahoo Finance
Why Tractor Supply (TSCO) is a Top Momentum Stock for the Long-Term - Yahoo Finance
TD Cowen maintains Buy on Molecular Partners, target CHF15 - Investing.com India
Molecular Partners reports 2024 annual results - Investing.com India
Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024 - GlobeNewswire Inc.
Wall Street Analysts Think Molecular Partners AG Sponsored ADR (MOLN) Could Surge 80.72%: Read This Before Placing a Bet - Yahoo Finance
Here's Why Seagate (STX) is a Strong Momentum Stock - Yahoo Finance
Molecular Partners, Orano Med announce presentation of MP0712 data - TipRanks
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket - Benzinga
US stock market gainers for the last week of April 2022 - Nairametrics
Novartis to push forward with covid drug after positive results - Luxembourg Times
Wall Street Analysts See a 96% Upside in Molecular Partners AG Sponsored ADR (MOLN): Can the Stock Really Move This High? - Yahoo Finance
Citi Appointed as Depositary Bank for Molecular Partners AG’s ADR Programme - Business Wire
Molecular Partners Ag Adr Stock (MOLN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):